Allison Luo

1.5k total citations
30 papers, 1.0k citations indexed

About

Allison Luo is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Allison Luo has authored 30 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 14 papers in Epidemiology and 8 papers in Immunology. Recurrent topics in Allison Luo's work include Inflammatory Bowel Disease (19 papers), Microscopic Colitis (11 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Allison Luo is often cited by papers focused on Inflammatory Bowel Disease (19 papers), Microscopic Colitis (11 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Allison Luo collaborates with scholars based in United States, Canada and Belgium. Allison Luo's co-authors include Jeffrey Kaine, Alan Kivitz, C. Birbara, William J. Sandborn, Sheila Gujrathi, Xiaolu Tao, Richard Aranda, Michael Yellin, Bruce E. Sands and Luisa Salter–Cid and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Gut.

In The Last Decade

Allison Luo

28 papers receiving 1.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Allison Luo 416 348 343 307 160 30 1.0k
Ibtissem Ghédira 251 0.6× 160 0.5× 276 0.8× 241 0.8× 47 0.3× 70 885
Pascale Loiseau 753 1.8× 214 0.6× 303 0.9× 210 0.7× 412 2.6× 45 1.6k
Virginia Lepage 464 1.1× 218 0.6× 202 0.6× 106 0.3× 58 0.4× 26 1.1k
Samantha Moore 795 1.9× 84 0.2× 338 1.0× 88 0.3× 154 1.0× 14 1.2k
Felicia Anna Tucci 194 0.5× 102 0.3× 378 1.1× 381 1.2× 64 0.4× 24 1.1k
Pascale Ghillani‐Dalbin 319 0.8× 67 0.2× 540 1.6× 268 0.9× 96 0.6× 41 1.2k
Micheline Lévy 395 0.9× 295 0.8× 205 0.6× 129 0.4× 304 1.9× 51 1.8k
M. McIlraith 362 0.9× 94 0.3× 225 0.7× 101 0.3× 130 0.8× 18 670
J Lysholm 273 0.7× 67 0.2× 613 1.8× 178 0.6× 232 1.4× 20 990
Laura Nuño 478 1.1× 94 0.3× 562 1.6× 159 0.5× 117 0.7× 60 944

Countries citing papers authored by Allison Luo

Since Specialization
Citations

This map shows the geographic impact of Allison Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Luo more than expected).

Fields of papers citing papers by Allison Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Luo. The network helps show where Allison Luo may publish in the future.

Co-authorship network of co-authors of Allison Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Allison Luo. A scholar is included among the top collaborators of Allison Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison Luo. Allison Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Moxin, Liqi Shu, M E Mawad, et al.. (2025). Impact of hospital readmission site on outcomes in acute ischemic stroke patients undergoing mechanical thrombectomy: a nationwide analysis. Journal of NeuroInterventional Surgery. 18(1). 195–201. 1 indexed citations
2.
3.
4.
Sands, Bruce E., Brian G. Feagan, Laurent Peyrin‐Biroulet, et al.. (2024). Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. New England Journal of Medicine. 391(12). 1119–1129. 23 indexed citations
5.
Luo, Allison, et al.. (2024). Management of a fractured microcatheter during middle meningeal artery embolization. Journal of NeuroInterventional Surgery. 16(12). 1214–1214.
6.
Feagan, B G, et al.. (2023). DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results. Journal of Crohn s and Colitis. 17(Supplement_1). i162–i164. 22 indexed citations
7.
Sands, Bruce E., Laurent Peyrin‐Biroulet, Silvio Danese, et al.. (2023). 477a A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMISUC, COHORT 1. Gastroenterology. 164(6). S–1570. 1 indexed citations
8.
Sands, Bruce E., Laurent Peyrin‐Biroulet, Silvio Danese, et al.. (2023). OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results. Journal of Crohn s and Colitis. 17(Supplement_1). i56–i59. 21 indexed citations
9.
Feagan, Brian G., Bruce E. Sands, Corey A. Siegel, et al.. (2023). S1143 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results. The American Journal of Gastroenterology. 118(10S). S875–S876. 1 indexed citations
10.
Luo, Allison, Robert S. Lester, Robert M. Schwab, et al.. (2020). Tu1852 PHARMACOKINETICS AND PHARMACODYNAMICS OF OPL-002, A HIGHLY SELECTIVE S1P1R MODULATOR, IN HEALTHY ADULT VOLUNTEERS.. Gastroenterology. 158(6). S–1188. 3 indexed citations
11.
Sandborn, William J., Paul Rutgeerts, Jean–Frédéric Colombel, et al.. (2017). Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. Journal of Crohn s and Colitis. 11(7). 811–819. 27 indexed citations
12.
Sandborn, William J., Jean‐Frédéric Colombel, Subrata Ghosh, et al.. (2015). Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. Journal of Crohn s and Colitis. 10(4). 418–428. 53 indexed citations
13.
Khanna, Reena, Guangyong Zou, Geert D’Haens, et al.. (2015). Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut. 65(7). 1119–1125. 73 indexed citations
14.
Mayer, Lloyd, William J. Sandborn, Karel Geboes, et al.. (2013). Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 63(3). 442–450. 119 indexed citations
15.
Weinblatt, Michael E., Larry W. Moreland, René Westhovens, et al.. (2013). Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program. The Journal of Rheumatology. 40(6). 787–797. 104 indexed citations
16.
Alten, Rieke, Clifton O. Bingham, Stanley Cohen, et al.. (2013). SAT0001 Antibody Response to Pneumococcal and Influenza Vaccination in Patients With RA Receiving Subcutaneous Abatacept. Annals of the Rheumatic Diseases. 72. A579–A579. 2 indexed citations
17.
Sandborn, William J., Jean‐Frédéric Colombel, Bruce E. Sands, et al.. (2012). Abatacept for Crohn's Disease and Ulcerative Colitis. Gastroenterology. 143(1). 62–69.e4. 111 indexed citations
18.
Keystone, Edward, Joel M. Kremer, Anthony S. Russell, et al.. (2012). Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Annals of the Rheumatic Diseases. 71(6). 857–861. 43 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ibtissem Ghédira Breakdown of academic impact, for papers by Pascale Loiseau Breakdown of academic impact, for papers by Virginia Lepage Breakdown of academic impact, for papers by Samantha Moore Breakdown of academic impact, for papers by Felicia Anna Tucci Breakdown of academic impact, for papers by Pascale Ghillani‐Dalbin Breakdown of academic impact, for papers by Micheline Lévy Breakdown of academic impact, for papers by M. McIlraith Breakdown of academic impact, for papers by J Lysholm Breakdown of academic impact, for papers by Laura Nuño
Rankless by CCL
2026